Annotation Detail

Information
Associated Genes
ERBB2
Associated Variants
ERBB2 AMPLIFICATION ( ENST00000269571.10 )
ERBB2 AMPLIFICATION ( ENST00000269571.10 )
Associated Disease
gastric adenocarcinoma
Source Database
CIViC Evidence
Description
TyTAN, a Phase III study in Asian patients, looked at addition of tyrosine kinase inhibitor lapatinib to chemptherapy in advanced HER2 positive gastric cancer. Primary endpoint was Overall Survival (OS). Participants had progressed under previous treatment and only a small percentage had seen first line trastuzumab. Patients were a mix of those having undergone gastrectomy and not. OS was not significantly different in the ITT population, but certain subpopulations showed significant differences. In the subset of patients showing a stronger immunohistochemistry result for HER2 (IHC3+), progression free survival was significantly different at 5.6 months for lapatinib + pacitaxel vs. 4.2 months for pacitaxel alone. The authors conclude that proof of concept for lapatanib addition to chemotherapy for certain subgroups is provided in this study.
Variant Origin
somatic
Variant Origin
Somatic
Evidence URL
https://civic.genome.wustl.edu/links/evidence_items/1023
Gene URL
https://civic.genome.wustl.edu/links/genes/20
Variant URL
https://civic.genome.wustl.edu/links/variants/306
Rating
3
Evidence Type
Predictive
Disease
Gastric Adenocarcinoma
Evidence Direction
Supports
Drug
Lapatinib
Evidence Level
B
Clinical Significance
Sensitivity/Response
Pubmed
24868024
Drugs
Drug NameSensitivitySupported
LapatinibSensitivitytrue